Replication of the POET-COPD Trial in Healthcare Claims Data
NCT05083429 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 8716
Last updated 2023-07-27
Summary
Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.
Conditions
Interventions
- DRUG
-
Salmeterol
Salmeterol inhaler dispensing claim is used as the reference
- DRUG
-
Tiotropium
Tiotropium dispensing claim is used as the reference
Sponsors & Collaborators
-
Brigham and Women's Hospital
lead OTHER
Principal Investigators
-
Shirley Wang, PhD, ScM · Brigham and Women's Hospital
Eligibility
- Min Age
- 40 Years
- Max Age
- 120 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-09-22
- Primary Completion
- 2021-08-09
- Completion
- 2021-08-09
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
PT003 MDI Dose Confirmation Study
NCT01349816 ·Status: COMPLETED ·Phase: PHASE2
-
28-day Repeat Dose Study of GSK573719
NCT01030965 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD
NCT02343458 ·Status: COMPLETED ·Phase: PHASE3
-
Changes in Cardiac Function in COPD Patients After Administration of Budesonide/Formoterol (Symbicort®) Versus Placebo
NCT01760304 ·Status: TERMINATED ·Phase: PHASE4
-
A Collection of Vital Status and Pulmonary Medication Usage Data for Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Withdrew Prematurely From Tiotropium Inhalation Solution Delivered by the Respimat Inhaler
NCT02172560 ·Status: COMPLETED
-
A Study to Assess the Effects of PT003 and Placebo MDI on Specific Image Based Airway Volumes and Resistance in Subjects With Moderate to Severe COPD
NCT02643082 ·Status: COMPLETED ·Phase: PHASE3
-
12 / 48 wk Pivotal PFT vs PBO in COPD II
NCT00782509 ·Status: COMPLETED ·Phase: PHASE3
-
Effect of Tiotropium Plus Salmeterol vs. Fluticasone/Salmeterol on Static Lung Volumes and Exercise Endurance in COPD
NCT00530842 ·Status: COMPLETED ·Phase: PHASE4
-
Efficiency of Twice Daily Formoterol Versus Once Daily Tiotropium in Patients With GOLD A/B COPD
NCT03258749 ·Status: UNKNOWN ·Phase: NA
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Repeat Doses of RV1729 for 28 Days in Patients With COPD
NCT02140346 ·Status: COMPLETED ·Phase: PHASE1
-
Anti-ST2 (MSTT1041A) in COPD (COPD-ST2OP)
NCT03615040 ·Status: COMPLETED ·Phase: PHASE2
-
SERETIDE Plus Tiotropium Versus Individual Components
NCT00325169 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the 24 Hour Spirometric Effect (FEV1) of Fluticasone Furoate/Vilanterol Inhalation Powder (100mcg Fluticasone Furoate (FF)/25mcg Vilanterol (VI)) Compared With Salmeterol/Fluticasone Propionate Inhalation Powder (50mcg Salmeterol/500mcg Fluticasone Propionate (FP))
NCT01342913 ·Status: COMPLETED ·Phase: PHASE3
-
Survival Of Subjects With Chronic Obstructive Pulmonary Disease (COPD)
NCT00268216 ·Status: COMPLETED ·Phase: PHASE3
-
The Effect of QVA149 on Health Related Quality of Life in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT01574651 ·Status: COMPLETED ·Phase: PHASE3
-
12 / 48 Week Pivotal PFT vs PBO in COPD I
NCT00782210 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of the Efficacy and Safety of QVA149 (110/50 μg o.d.) vs Tiotropium (18 µg o.d.) + Salmeterol/Fluticasone Propionate FDC (50/500 µg b.i.d.) in Patients With Moderate to Severe COPD
NCT02603393 ·Status: COMPLETED ·Phase: PHASE4
-
A 24-week Study to Evaluate the Efficacy and Safety of GSK573719/GW642444 125/25 mcg and 62.5/25mcg Inhalation Powder Compared With Placebo in Subjects With COPD
NCT01636713 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Assess the Safety and Tolerability of PT010, PT009 and PT003 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
NCT02536508 ·Status: COMPLETED ·Phase: PHASE3
-
Pharmacovigilance Study to Evaluate Safety of SERETIDE in Participants With Chronic Obstructive Pulmonary Disease (COPD)
NCT00662805 ·Status: COMPLETED
-
Safety and Tolerability of Repeat Dosing of GSK233705/GW642444 in COPD
NCT00749411 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy, Safety and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)
NCT01572792 ·Status: COMPLETED ·Phase: PHASE3
-
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
NCT00676052 ·Status: COMPLETED ·Phase: PHASE2
-
A Safety, Pharmacokinetic and Pharmacodynamic Study of PUR0200 in COPD Patients
NCT01921712 ·Status: COMPLETED ·Phase: PHASE1
-
A Six-week Study Comparing the Efficacy and Safety of Tiotropium Plus Formoterol to Salmeterol Plus Fluticasone in Chronic Obstructive Pulmonary Disease (COPD)
NCT00239421 ·Status: COMPLETED ·Phase: PHASE4